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Although originally considered a structural component of gap junctions, connexin
hemichannels (HCs) are now recognized as functional entities capable of influencing
metabolic gradients within the CNS, allowing direct communication between the intra-
and extracellular milieus. Besides connexins, HCs can also be formed by pannexins,
which are not capable of gap junction assembly. Both positive and negative effects have
been attributed to HC activity in the context of neurodegenerative diseases. For example,
HCs can exert neuroprotective effects by promoting the uptake of neurotoxic molecules,
whereas chronic HC opening can disrupt molecular gradients leading to cellular dysfunction
and death. The latter scenario has been suggested for multiple neurodegenerative
disorders, including Alzheimer’s disease (AD) and more recently, lysosomal storage
disorders, which are the focus of this perspective. Currently available evidence suggests
a complex role for HCs in neurodegenerative disorders, which sets the stage for future
studies to determine whether targeting HC action may improve disease outcomes.
Keywords: connexin, hemichannels, neurodegeneration, lysosomal storage disease, Alzheimer’s disease
INTRODUCTION
Hemichannels (HCs) are composed of six connexin (Cx) sub-
units that assemble into hexameric pores that traffic to the
plasma membrane where they can remain uncoupled or pair
with adjacent HCs on neighboring cells to form gap junction
channels (Contreras et al., 2003). Besides Cxs, HCs can also
be formed by pannexins (Panx), which are not capable of gap
junction assembly. This Perspective focuses on HC involvement
in neurodegenerative diseases; therefore, gap junction activ-
ity will not be discussed here but has been the subject of
several excellent reviews related to CNS disorders (Orellana
et al., 2009; Eugenin et al., 2012). HCs are permeable to small
hydrophilic molecules, such as ATP, Ca2+, glutamate, glucose,
and glutathione, which are critical for CNS homeostasis by
maintaining ionic and metabolic gradients and can also con-
trol autocrine/paracrine signaling (Retamal et al., 2007; Kielian,
2008; Rouach et al., 2008; Sánchez et al., 2009; Schalper et al.,
2010; Orellana et al., 2011a; Bennett et al., 2012; Fiori et al.,
2014).
Currently, a total of 10 Cx and 2 Panx isoforms have been
reported to be expressed in the brain (Giaume et al., 2013). The
repertoire of Cx protein expression is distinct among various CNS
cell types; however, the functional impact of these differences
remains to be fully defined. For example, astrocytes primarily
express Cx43 and Cx30, as well as, Cx26, Cx40, Cx45 and Cx46;
microglia utilize Cx43, Cx36, and Cx32; and neurons express
Cx36, Cx26, Cx45, and Cx57 (Rouach et al., 2002; Mika and
Prochnow, 2012). Studies have shown that a selective pattern
of Cx HC expression may orchestrate extracellular signaling
networks between various glial cell types and/or neurons in a
homotypic or heterotypic fashion (Giaume et al., 2013; May
et al., 2013). Panx expression has been reported in neurons,
astrocytes, and more recently microglia (Orellana et al., 2009,
2011b; Sáez et al., 2013b); however, an outstanding question is
whether Cx/Panx HC function differs within various CNS cell
subpopulations. For example, it is becoming clear that astro-
cytes exhibit regional heterogeneity and it will be interesting
to determine whether this is associated with differences in the
molecular composition of Cx/Panx HCs and/or sensitivity to HC
opening.
Originally considered a structural component of gap junc-
tions, strong evidence has emerged to support a role for HCs in
maintaining cellular and tissue homeostasis, by allowing cells to
directly communicate with their surrounding microenvironment
and relay signals via the release of molecules that activate extracel-
lular receptors in an autocrine/paracrine manner (Orellana et al.,
2009). In the last decade, several reports have linked inflammation
and dysregulated HC activity in the CNS. The summation of this
work suggests that HCs have a dual role in regulating molecular
gradient homeostasis in the context of neurodegenerative dis-
eases. On the one hand, transient HC activity has been suggested
to be protective during normal physiologic states as well as acute
insults or inflammation. For example, astrocyte HCs have been
shown to promote glucose uptake, which is considered a second
glucose-lactate pathway for neurons. In addition, HCs could
release lactate, which could also be beneficial for neurons (Rouach
et al., 2008; Giaume et al., 2013). Proinflammatory cytokines
(i.e., IL-1β and TNF-α) are known to activate glia and promote
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HC opening, which may serve as a means to propagate glial
activation or neuron activity by the release of bioactive molecules
acting in an autocrine/paracrine manner. Conversely, sustained
HC opening during chronic neurodegenerative diseases may pro-
mote disease progression by perturbing metabolic gradients and
the exaggerated release of toxic molecules to induce cell death
(Figure 1).
HC INVOLVEMENT IN NEURODEGENERATIVE DISEASES
A common denominator linking neurodegenerative diseases and
HC opening is neuroinflammation, characterized by microglial
and astrocyte activation and secretion of inflammatory mediators.
Microglia, the resident macrophages of the CNS parenchyma,
phagocytose cellular debris and produce a wide array of proin-
flammatory molecules (Kettenmann et al., 2011; Lyman et al.,
2014). These mediators, which include cytokines (i.e., IL-β, IL-6,
and TNF-α), reactive oxygen and nitrogen species, glutamate,
and neurotrophic factors enhance cell mobility, phagocytosis, and
can be neuroprotective when carefully regulated (Kielian, 2008;
Mika and Prochnow, 2012). Under physiological conditions,
transient astrocyte activation plays a pivotal role in maintaining
neurotransmitter levels at the tripartite synapse and metabolite
trafficking. However, during neuroinflammation, chronic proin-
flammatory mediator release may cause dramatic and potentially
detrimental alterations in the way microglia and astrocytes com-
municate and regulate homeostasis via HC opening (Figure 1).
The end result is a milieu that can lead to cellular toxicity or
dysfunction, which over time, can manifest as cognitive and/or
motor decline depending on the CNS site affected (Finn et al.,
2011; Orellana et al., 2011a; Xiong and Kielian, 2013).
HC ACTIVITY IN LYSOSOMAL STORAGE DISEASES
Lysosomal storage diseases (LSDs) encompass a large group of
inherited metabolic disorders characterized by the accumulation
of storage material within lysosomes. Collectively, LSDs afflict
1 out of every 6700 live births and approximately 75% of the
LSDs currently identified impact CNS function (Meikle et al.,
1999; Sands and Haskins, 2008). Although a relatively new area of
investigation, recent studies have reported perturbed HC activity
in two distinct LSDs, namely Juvenile Neuronal Ceroid Lipofusci-
nosis (JNCL) and Niemann-Pick type C (NPC).
JNCL is caused by a mutation in the CLN3 gene that most
commonly spans exons 7–8 (Janes et al., 1996; Cotman et al.,
2002; Drack et al., 2013). Brains of JNCL patients at autopsy
as well as JNCL mouse models have shown that areas of acti-
vated microglia and astrocytes correlate with regions of neuron
loss, along with elevated levels of IL-1β and ceramide, the lat-
ter representing a key lipid mediator involved in inflammation
and apoptosis (Pontikis et al., 2004; Mencarelli and Martinez-
Martinez, 2013; Xiong and Kielian, 2013). A recent study from our
laboratory using primary microglia from the CLN3∆ex 7/8 mouse
model of JNCL demonstrated that when challenged with “danger
signals” elevated in the brains of JNCL patients (i.e., ceramide
and neuron lysate), CLN3∆ex 7/8 microglia released significantly
more proinflammatory mediators compared to wild type cells,
which remained largely non-responsive (Xiong and Kielian,
FIGURE 1 | Balance of hemichannel (HC) regulation in the CNS. HC
opening is under tight control, where acute activity helps to maintain
molecular gradients, cell homeostasis, and autocrine/paracine signaling. A
slight disruption of this balance, as can occur during neurodegenerative
diseases and inflammatory signals, causes increased HC opening. Chronic
HC activity can result in the ablation of vital molecular gradients, toxin release
into the extracellular milieu, and potentiation of glial activation and neuron
death.
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2013). Furthermore, CLN3∆ex 7/8 microglia displayed increased
HC opening, which was associated with elevated glutamate and
ATP release. Glutamate accumulation can cause neuronal excito-
toxicity and a role for glutamate excitotoxicity in JNCL progres-
sion has been previously reported (Finn et al., 2011).
Another recent study from our laboratory revealed a tran-
sient increase in astrocyte HC activity in disease-affected regions
of the CLN3∆ex 7/8 mouse brain as early as postnatal day 30,
which significantly preceded neuron loss that is not evident until
6–8 months of age (Burkovetskaya et al., 2014). However, this
increase was transient, since CLN3∆ex 7/8 astrocyte HC function
began to decline at postnatal day 60, eventually falling below
levels observed in wild type mice by postnatal day 90, suggesting a
progressive decline in astrocyte function at later stages of disease.
Treatment of CLN3∆ex 7/8 mice with the HC inhibitor INI-0602,
a blood-brain barrier permeable derivative of carbenoxolone
(Takeuchi et al., 2011), significantly reduced lysosomal storage
material accumulation in specific brain regions. In addition,
astrocyte gap junction communication was significantly elevated
in CLN3∆ex 7/8 mice, which was predicted to occur via HC closure,
although this was not apparent in acute brain slices ex vivo
(Burkovetskaya et al., 2014). Nonetheless, aberrant HC activity
in astrocytes and microglia may contribute to neuron loss in
JNCL, particularly when considering that glial activation predates
neuron death by several months in this mouse model (Pontikis
et al., 2004). Unresolved questions are whether changes in HC
function are responsible for the brain metabolic disturbances
reported in JNCL and whether HC involvement extends to other
CNS cell types (i.e., neurons and microglia).
NPC is caused by a mutation in the NPC1 or NPC2 genes,
with the former being most common. NPC1 and NPC2 are
required for cholesterol clearance and their absence causes the
accumulation of cholesterol and other lipids in lysosomes (Rosen-
baum and Maxfield, 2011). Similar to JNCL, neuroinflammation
has been implicated in NPC pathology (Baudry et al., 2003).
However, a recent study by Sáez et al. (2013a) suggested that
the increase in HC activity observed in NPC might not be
related to neuroinflammation per se but rather, the mutation itself
(Sáez et al., 2013a). Specifically, primary astrocyte cultures from
NPC−/− mice displayed increased HC activity under baseline
conditions compared with cells from wild type and NPC+/−
animals. In addition, acute hippocampal slices from NPC−/−
mice at postnatal day 2 revealed increased astrocyte HC activity
that could be blocked using the general HC blocker La3+ and
Cx43 antibody. These data imply the involvement of Cx43 HCs
and suggest that dysfunctional HCs occur at the earliest phase
of NPC disease. It remains to be determined whether this HC
activity represents an attempt by astrocytes to regain homeostasis
in the context of NPC mutation or whether HC opening sets the
stage for downstream neuropathology. Nevertheless, the available
evidence supports a role for HCs in two distinct LSDs that have
devastating consequences on the CNS (Finn et al., 2011; Sáez
et al., 2013a; Burkovetskaya et al., 2014).
ALZHEIMER’S DISEASE AND HC FUNCTION
Alzheimer’s disease (AD) is currently the leading cause of demen-
tia in adults over the age of 65 years (Tiiman et al., 2013).
Hallmark symptoms of AD include memory impairment, loss of
abstract thought and language skills, and alterations in person-
ality (Welander et al., 2009). Pathologically, AD is characterized
by the extracellular accumulation of amyloid-beta (Aβ) peptide
into senile plaques and the intracellular hyperphosphorylation of
tau protein into neurofibrillary tangles. These aggregates cause
neuronal damage, generation of reactive oxygen and nitrogen
species, neuroinflammation, and defects in cell-cell communica-
tion (Selkoe, 2001; Small and Duff, 2008; Quintanilla et al., 2012;
von Bernhardi and Eugenin, 2012). The underlying mechanisms
that elicit plaque and tangle accumulation in AD remain elusive.
Using an APP/PS1 mouse model of AD, Mei et al. (2010)
observed increased Cx43 and Cx30 expression in astrocyte pro-
cesses invading the plaque core and Cx43 immunoreactivity has
also been associated with plaques in human AD tissues (Nagy
et al., 1996; Mei et al., 2010). Along with increased Cx expression,
Aβ has been reported to increase HC activity in neurons, astro-
cytes, and microglia (Orellana et al., 2011b). Similar to the series
of events reported in JNCL above, Aβ elicits a proinflammatory
response in resident glial cells typified by inflammatory cytokine,
glutamate, and ATP release, which subsequently triggers HC
opening in neighboring neurons. It is postulated that neuron
HC opening is one factor responsible for neuron death that can
further enhance neuroinflammation and propagate the neurode-
generative process.
Indeed, HC involvement in AD was also demonstrated by
Takeuchi et al. (2011), where treatment of APP/PS1 mice with the
HC inhibitor INI-0602 improved cognitive function (Takeuchi
et al., 2011). In addition, INI-0602 blocked neurotoxic gluta-
mate release from activated microglia both in vitro and in vivo.
Although still in the relatively early stage of exploration, these
findings suggest that targeting HCs could prove to be beneficial
in combating AD symptoms and progression.
CURRENT CHALLENGES IN THE FIELD OF HC BIOLOGY
Since the discovery that HCs can exert functional activity, sig-
nificant efforts have been made to characterize their roles in
neurodegenerative diseases; however, many limitations still exist.
One primary issue is the availability of reagents that can specif-
ically block HC action. Many of the pharmacological inhibitors
currently used to study HCs also affect gap junctions, which must
be considered when these compounds are used experimentally.
In addition, many widely used inhibitors are not selective for
a particular HC type, which leaves the identification of HC
protein composition in question. A potential solution is the use
of Cx-specific antibodies or Cx/Panx mimetic peptides that can
selectively block HC permeability (Sáez et al., 2013a). A second
difficulty when studying Cx HCs is the methods used to evaluate
their activity, since it is challenging to distinguish between Cx gap
junction and HC action. For example, HCs are often reported
by increases in either Cx immunoreactivity in brain tissues or
Western blots. However, both gap junctions and HCs are com-
prised of Cxs making it problematic to discriminate between
the two. Functionally, the primary method used to measure HC
activity is ethidium uptake. However, based on its low molecu-
lar weight, numerous types of open channels are permeable to
ethidium, which calls to caution how HC ethidium uptake data
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is interpreted. Here the combination of ethidium uptake coupled
with a Cx/Panx selective inhibitor can begin to narrow the action
to Cx/Panx channels; however, for the reasons mentioned above,
identification of HC vs. gap junction channels remains an area of
debate. Perhaps the best means to quantifying HC activity is single
channel electrophysiology. This approach is feasible in cultured
cells; however, it is significantly more challenging in brain slices,
as reflected in a study by Kang et al. (2008) where electrophys-
iological evidence of HC activity was obtained in only 18 out
of 700 recordings (Kang et al., 2008). Regardless of these tech-
nical limitations, careful consideration should be given to select
the best model system to examine HC function. Many studies
characterizing the functional roles of HCs have been performed
in reconstituted liposomes or cell cultures (Fiori et al., 2014).
While these methods provide useful insights, they are not able
to recapitulate in vivo environments. Live tissue slices are better
representative of in vivo events and have provided more functional
data; however, this approach also has its limitations. Specifically,
upon excision, the brain slice begins to slowly deteriorate due to
cell damage inflicted during the cutting process concomitant with
microglial activation, which may impact the results obtained. To
ensure tissue viability for an extended period of time, slices are
continuously bathed with artificial cerebrospinal fluid which is
equilibrated with CO2 and care should be taken to evaluate cells
that are positioned well below the cut surface to avoid signals
from damaged regions. Future research avenues could be directed
towards discovering new minimally invasive methods for studying
HCs in vivo such as two-photon microscopy or channel tracers
that can be imaged using functional magnetic resonance imaging
(MRI) or single photon emission computed topography (SPECT;
Kielian, 2008).
OUTSTANDING QUESTIONS AND CONCLUSIONS
Significant progress has been made towards elucidating the
functional role of HCs in neurodegenerative diseases; however,
many unanswered questions remain. The first is whether HC
dysfunction is an active contributor to disease pathology or
merely a consequence. In the case of AD, neuroinflammation
indirectly increases HC channel activity in multiple cell types
(Orellana et al., 2011a; Quintanilla et al., 2012). Numerous
reports by others also support a similar relationship where HC
activation and neuroinflammation act as co-factors, where one
event influences the progression of the other. If correct, then
therapeutically targeting HCs would only potentially slow disease
progression but not be curative. In contrast, a direct connection
between HC activity and inflammation does not appear to exist
in NPC. Specifically, increased HC activity in neurons, astro-
cytes, and microglia was not induced by proinflammatory stim-
ulators, suggesting that HC action precedes neuroinflammation
in NPC. A similar case for changes in HC activity predating
neuroinflammation is seen in JNCL, since HC dysfunction was
observed early, whereas overt inflammation is not evident until
later stages of disease (Xiong and Kielian, 2013; Burkovetskaya
et al., 2014). The similarities between these two LSDs suggest
that a core response may be operative that is not tied to inflam-
mation per se. Nonetheless, as the intensity of the inflamma-
tory response increases with advancing disease, it is likely that
inflammatory mediators will impact HC activity, perhaps in a
fashion that has already been described in AD and glial cell
culture models (Figure 1). The complexity of HC composition
combined with distinct expression patterns on various CNS cell
types suggest that new insights are bound to emerge to account
for this diversity in HCs in terms of CNS homeostasis and
pathology.
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